Related Experiment Video
Updated: Feb 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic
Gabriel Pardo1, David E Jones2
1OMRF Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, 820 NE 15th Street, Oklahoma City, OK, 73104, USA. gabriel-pardo@omrf.org.
Abstract:
Unfortunately, the online published article has errors in Table 2. The Peginterferon is listed as IM, when it should be SC.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Overview and Classification
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

